NCT06771518RecruitingPhase 2
Association of Thoraco-mediastinal Radiotherapy With Maintenance Immunotherapy Treatment With Atezolizumab
Lung Microcytoma Extensive Disease: Prospective Study of Association of Thoraco-mediastinal Radiotherapy With Maintenance Immunotherapy Treatment With Atezolizumab
Source: ClinicalTrials.gov · Last updated 5 Jun 2026
Brief summary (registry, in English)
Investigate the role of consolidative radiotherapy treatment at the thoraco-mediastinal level in the patient suffering from lung microcytoma - extensive disease and treated with chemo-immunotherapy with atezolizumab, in association with maintenance therapy with atezolizumab.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 37 (estimated)
- First submitted
- 23 Feb 2024
- Start date
- 15 Dec 2021
- Primary completion date
- 15 Dec 2026
- Lead sponsor
- Regina Elena Cancer Institute
- Diseases
- Lung cancer
- NCT number
- NCT06771518
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 37
- From 15 Dec 2021 to the primary completion date, 15 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous radiotherapy treatment at the thoraco-mediastinal level;
Other illness
- In disease progression after chemo-immunotherapy treatment.
Who the study is looking for
- Histological diagnosis of lung microcytoma;
- Age ≥18 years;
- Performance status according to ECOG 0-2;
- Extended disease at the time of first line oncological treatment;
- Initial staging and restaging after chemo-immunotherapy with CT, CT-PET FDG and brain MRI;
- In at least partial response (defined according to the Recist criteria \[18\]) after treatment chemoimmunotherapy according to the Impower 133 scheme;
- Haematological, respiratory toxicity ≤ G1, other toxicities ≤ G2 at the time of treatment radiotherapy;
- Pulmonary function tests at the time of radiotherapy treatment compatible with irradiation: FEV≥1.2 l or \>40%, DLCO≥50%;
- Written informed consent.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Regina Elena National Cancer Institute Coordinator of this site? Confirm its status | Rome | Italy | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.